Abstract
4579 Background: Both regimens, estramustine plus docetaxel (Arm 1) and mitoxantrone plus prednisone (Arm 2), are known to palliate pain in hormone refractory metastatic prostate cancer. In SWOG 9916, Arm 1 was hypothesized to have greater clinical efficacy as well as equivalent or better palliation of disease-related symptoms. Methods: Men with stage D1 or D2 prostate cancer were randomized to one of the two regimens. We report preliminary data for the Present Pain Intensity (PPI) scale of the McGill Pain Questionnaire and the Global QOL (GQOL) scale score from the EORTC QLQ-C30 at baseline, week 10, months 6, and 12. Results: 333 eligible patients were registered to each arm. Arm 1 had statistically better survival (72% vs. 62% at year 1). The table presents cross-sectional means and sample size for patients by treatment arm and time point. Arm 1 has better submission rates than Arm 2, consistent with Arm 1's longer survival. Data not shown suggest that patients who submitted fewer forms over time had w...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
